Regeneron Pharmaceuticals has built its success on a foundation of innovative drug development, with key products including Eylea for eye diseases and Dupixent for various inflammatory conditions.

Whether you’re managing a sluggish metabolism, fluctuating hormones, or decreased muscle mass, it’s not uncommon to feel like your body is fighting against you. But don’t despair — there ...

The Standard's journalism is supported by our readers. When you purchase through links on our site, we may earn an affiliate commission. TVs seem to be getting bigger and bigger every year, but ...

FYB203 (aflibercept) approved in the UK for the treatment of neovascular age-related macular degeneration (nAMD) and several other severe retinal diseases UK market authorization follows successful ...

The Seoul Central District Court ruled against Regeneron, which had sought to block Samsung Bioepis from producing and selling a biosimilar referencing the US firm’s Eylea, a blockbuster medicine used ...

THURSDAY 20 FEBRUARY, 2025 - INCHEON, SOUTH KOREA – Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt ...

INCHEON, South Korea I February 18, 2025 I Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt ® ...

The treatment is a biosimilar that could compete with Regeneron Pharmaceuticals’ Eylea. Teva and Alvotech have been working together in a strategic partnership since 2020. Teva Pharmaceutical ...

The trial, designed to compare the efficacy, safety, and immunogenicity of AVT06 with Eylea, reached the main goal, according to its topline data from January 2024. The duo said the FDA process to ...

The U.S. Food and Drug Administration (FDA) has approved for review a Biologics License Application (BLA) for AVT06, Alvotech’s proposed biosimilar to Eylea (aflibercept), a biologic used to treat eye ...

"We are extremely pleased with this new step in the development of our biosimilar candidate to Eylea ®, as better access will benefit patients and their caregivers," said Joseph McClellan ...